MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Inc. (RPTX)

|||

Cash Flow Overview

Change in Cash
$5,169K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Income taxes
    • Net loss for the period
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Gain on termination of collabora...
    • Accounts payable
    • Others
Cash Flow
2025-09-30
2025-06-30
Net loss for the period
3,258
-46,787
Share-based compensation expense
1,409
6,047
Depreciation expense
72
2,222
Non-cash lease expense
299
1,295
Foreign exchange gain
-39
117
Net accretion of marketable securities
480
1,006
Gain on sale of technology and other assets
130
5,666
Gain on termination of collaboration agreement
3,257
-
Impairment loss on rou asset
330
-
Prepaid expenses
1,052
-3,006
Other current receivables
-1,463
-67
Other non-current assets
0
-179
Deferred collaboration cost recovery
-
3,257
Accounts payable
-2,667
382
Accrued expenses and other current liabilities
-2,223
-7,652
Operating lease liability, current portion
-302
-1,223
Income taxes
9,149
609
Operating lease liability, net of current portion
0
-88
Deferred revenue
0
0
Net cash used in operating activities
2,651
-45,475
Proceeds from sale of technology and other assets
0
1,000
Proceeds from maturities of marketable securities
10,150
73,662
Purchase of marketable securities
7,613
46,456
Net cash provided by investing activities
2,537
28,206
Proceeds from exercise of stock options
0
0
Proceeds from issuance of common stock under the 2020 employee share purchase plan
30
79
Net cash provided by financing activities
30
79
Effect of exchange rate fluctuations on cash held
-49
129
Net decrease in cash and cash equivalents
5,169
-17,061
Cash and cash equivalents at beginning of period
84,717
-
Cash and cash equivalents at end of period
72,825
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Income taxes$9,149K Proceeds from maturitiesof marketable...$10,150K Net loss for theperiod$3,258K Other currentreceivables-$1,463K Share-based compensationexpense$1,409K Impairment loss on rou asset$330K Non-cash lease expense$299K Depreciation expense$72K Foreign exchange gain-$39K Proceeds from issuance ofcommon stock under the...$30K Net cash used inoperating activities$2,651K Net cash provided byinvesting activities$2,537K Canceled cashflow$13,368K Net cash provided byfinancing activities$30K Canceled cashflow$7,613K Net decrease in cashand cash...$5,169K Canceled cashflow$49K Gain on terminationof collaboration...$3,257K something is missing-$3,257K Accounts payable-$2,667K Accrued expenses andother current...-$2,223K Prepaid expenses$1,052K Net accretion ofmarketable securities$480K Operating leaseliability, current portion-$302K Gain on sale oftechnology and other assets$130K Purchase of marketablesecurities$7,613K Effect of exchange ratefluctuations on cash held-$49K